About Check-Cap
Check-Cap is a company based in Haifa (Israel) founded in 2005. Check-Cap has raised $9.88 million across 15 funding rounds from investors including GE Healthcare, General Electric and Fosun Pharmaceutical. Check-Cap offers products and services including C-Scan System. Check-Cap operates in a competitive market with competitors including IGM Biosciences, New Element Medicine, Zymedi, Brenus Pharma and Promis Diagnostics, among others.
- Headquarter Haifa, Israel
- Stage Public
- SectorsHealthcare
- Website check-cap.com
- Social LinkedIn X
- Legal Name Check-Cap Ltd.
- Net Profit-$25.15 M (USD)-43.15as on Dec 31, 2024
- EBITDA-$9.3 M (USD)47.3as on Dec 31, 2024
- Total Equity Funding$9.88M (USD)
in 15 rounds
- Latest Funding Round$9.63M (USD), Post-IPO
Jul 2020
- InvestorsGE Healthcare
& 7 more
Products & Services of Check-Cap
Check-Cap offers a comprehensive portfolio of products and services, including C-Scan System.
Preparation-free test for detecting precancerous polyps in cancer screening
Funding Insights of Check-Cap
Check-Cap has successfully raised a total of $9.88M across 15 strategic funding rounds. The most recent funding activity was a Post-IPO round of $9.63 million completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $9.88M
- Total Rounds 15
- Last Round Post-IPO — $9.63M
- First Round $9.88M
(Mar 2011)
- Investors Count 8
Latest 10 of 15 funding rounds of Check-Cap with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2020 | $9.63M | Post-IPO | – | – | – |
| May 2020 | $3M | Post-IPO | – | – | – |
| Apr 2020 | $4.5M | Post-IPO | – | – | – |
| Apr 2020 | $4M | Post-IPO | – | – | – |
| Dec 2019 | $4.75M | Post-IPO | – | – | – |
| Feb 2019 | $7.5M | Post-IPO | – | – | – |
| Nov 2017 | $2.13M | Post-IPO | – | – | – |
| Jun 2017 | $2.69M | Post-IPO | – | – | – |
| Aug 2016 | $5.9M | Post-IPO | – | – | – |
| Aug 2016 | $1.25M | Grant | – | – |
8 investors in total: 8 institutional.
Investors in Check-Cap
Check-Cap has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include GE Healthcare, General Electric and Fosun Pharmaceutical.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Pontifax Venture Capital is focused on life sciences investments. | – | pontifax.com | Herzeliya, Israel | |
Investments are directed toward Israeli technology startups by Docor. | – | docor.com | Tel Aviv, Israel | |
- | – | economy.gov.il | - | |
Research, development, production, and sale of pharmaceuticals are provided. | 1994 | fosunpharma.com | Shanghai, China | |
Materials management solutions are provided for healthcare organizations. | 1892 | gehealthcare.com | Chicago, United States | |
Diversified operations are conducted across multiple industries worldwide. | 1892 | ge.com | United States | |
Provides comprehensive wealth management, planning, and advisory services to clients. | – | thecounterpointfunds.com | Milwaukee, United States | |
- | – | m-a-worldwide.com | - |
Investor details for Check-Cap
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Check-Cap
13 people are tracked at Check-Cap (4 in leadership, 9 in team).
| Name | Role | Group |
|---|---|---|
Yoav Kimchy | Founder and Chief Technology Officer | Leadership |
Alex Ovadia | CEO | Leadership |
Michael Smirnov | Director Project Management | Leadership |
ריקי הובר | Payroll accountant and chief accountant | Leadership |
Liliya Popov | Manufacturing Specialist | Team |
Yanis Zaslavsky | Manufacturing Test Debugger/Engineer | Team |
Avner Elgali | mechanical group manager | Team |
Noa Reshef | HR Manager | Team |
Ilan Attal | Engineering Manager | Team |
Regina Agalarian | QC Engineer | Team |
Vladimir Yakhlial | Mechanical Engineer | Team |
Nitzan Gorani ניצן גורני | V&V Engineer | Team |
Riki Hober | Senior & Payroll Bookkeeper | Team |
Complete people profiles for Check-Cap
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Check-Cap
Check-Cap is a publicly listed company on the NASDAQ with ticker symbol CHEK in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date19 Feb 2015
- Listed onNASDAQ: CHEK
- Listed entityCheck-Cap Ltd.
- Exchange sectorHealth technology
- ISINIL0011336851
- Share price$1.61 (+1.9% on the day) · 2025-11-28
- Market capitalisation$11.3M
- Volume (last session)58,966
- Analyst consensusNeutral
Financials of Check-Cap
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2024 | – | -$25.1M | -$9.3M |
| 2023 | – | -$17.6M | -$17.6M |
| 2022 | – | -$19.1M | -$19.6M |
| 2021 | – | -$17.2M | -$17.1M |
| 2020 | – | -$13.8M | -$13.8M |
Detailed financial statements for Check-Cap
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Check-Cap
4 dated milestones of Check-Cap across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Check-Cap is founded.
- Funding First funding round of $9.9M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $9.6M.
Competitors of Check-Cap
Check-Cap operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as IGM Biosciences, New Element Medicine, Zymedi, Brenus Pharma and Promis Diagnostics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| igmbio.com | 2010 | Mountain View, United States | $102.67M | 181 | Antibodies for cancer and infectious disease treatments are developed. | |
| atombp.com | 2012 | Zhenjiang, China | $152.05M | – | Drugs for cancer and metabolic diseases are developed. | |
| zymedi.com | 2019 | Incheon, South Korea | $29.54M | – | Therapeutics for multiple diseases are developed using Aminoacyl-tRNA Synthetase technology. | |
| brenus-pharma.com | 2020 | Issoire, France | $25M | – | Immunotherapy for cancer treatment is developed by Brenus Pharma. | |
| promisdx.com | 2019 | Pasadena, United States | $10.8M | 9 | Non-invasive diagnostics for colorectal cancer screening are developed. | |
| augere.md | 2018 | Oslo, Norway | $2.08M | 4 | AI-based real-time cancer detection for endoscopy is provided. | |
| evqlv.com | 2019 | New York, United States | – | – | AI-based immunotherapies for cancer and immune diseases are developed. | |
| solvdhealth.com | 2014 | Carlsbad, United States | – | – | Diagnostic technologies for early disease detection are provided. | |
| miwendo.com | 2019 | Barcelona, Spain | $121,456 | – | Electromagnetic endoscopy is developed for colorectal cancer detection. |
Detailed competitors of Check-Cap
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Check-Cap
Complete news archive for Check-Cap
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Check-Cap
10 companies that operate in the same segment as Check-Cap (Gastroenterology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for gastrointestinal disorders, including linaclotide, are developed. | 1998 | Cambridge, Massachusetts, United States | USD 206.25 M | USD 296.15 M | 253 | |
Implantable battery-powered pumps for ascites removal are developed. | 2006 | Zurich, Switzerland | USD 35.5 M | – | – | |
Sacral neuromodulation devices are developed for urinary and bowel control. | 2013 | Irvine, California, United States | USD 143.47 M | – | – | |
Provider of a deep learning platform for detecting circulating cancer-related markers | 2014 | United States | USD 1.35 B | – | 533 | |
Developer of electrosurgical system and range of flexible endoscopic instruments | 2003 | Chepstow, Monmouthshire, United Kingdom | USD 20.84 M | USD 8.08 M | 141 | |
Non-invasive biomarker tests for colorectal cancer are developed. | 2015 | St. Louis, Missouri, United States | USD 218.95 M | – | – | |
Pendulum is focused on developing advanced probiotic solutions. | 2012 | San Francisco, California, United States | USD 109.5 M | – | 55 | |
Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed. | 2007 | Fremont, California, United States | USD 61.1 M | USD 407.32 M | 395 | |
Developer of therapeutics for the treatment of gastrointestinal and infectious diseases | 2009 | Ramat Gan, Tel Aviv District, Israel | USD 13.5 M | USD 288.27 K | 35 | |
Biologics are developed for cardio-metabolic and liver diseases. | 2007 | San Francisco, California, United States | USD 358.87 M | USD 330.53 M | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Check-Cap
Check-Cap was founded in 2005 and raised its 1st funding round 6 years after it was founded.
Check-Cap is headquartered in Haifa, Israel. It is registered at Haifa, Haifa District, Israel.
Check-Cap is a funded company, having raised a total of $9.88M across 15 funding rounds to date. The company's 1st funding round was a Grant of $1.25M, raised on Mar 2011.
Check-Cap was founded in 2005 in Haifa, Israel, and operates in the medical technology sector. Non-invasive imaging capsules are developed for colorectal cancer screening, eliminating the need for bowel preparation or invasive procedures. Polyps are detected with high sensitivity through structural examinations. The technology has been validated in animal studies, supporting early cancer detection efforts.
Check-Cap's top competitors include IGM Biosciences, Zymedi and Brenus Pharma.
Check-Cap offers C-Scan System.
Yes, Check-Cap is publicly traded on NASDAQ under the ticker symbol CHEK.
Check-Cap has 8 investors. Key investors include GE Healthcare, General Electric, Fosun Pharmaceutical, Ministry of Economy and industry, and Pontifax Venture Capital.
Check-Cap operates through Check-Cap Ltd.